{"id":"W4316927819","doi":"10.1007/s13555-022-00883-y","title":"Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dalhousie University","funders":"UCB Pharma; Sun Pharma; Mitsubishi Tanabe Pharma Corporation; Taiho Pharmaceutical; Celgene; Eisai; Sanofi; Amgen; Pfizer; Meiji Seika Pharma; Kyowa Hakko Kirin; LEO Pharma; Torii Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ustekinumab; Plaque psoriasis; Placebo; Medicine; Psoriasis; Dermatology; Internal medicine; Alternative medicine; Pathology; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023721,0.0008140183,0.002513213,0.0002078841,0.0004757264,0.0006833897,0.0005871002,0.0007401825,0.002158348],"category_scores_gemma":[0.000959134,0.000474089,0.001419769,0.0003876784,0.0006941259,0.0004231419,0.0002979102,0.001610506,0.00033836],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005282797,"about_ca_system_score_gemma":0.001334832,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001131846,"about_ca_topic_score_gemma":0.002488557,"domain_scores_codex":[0.9994076,0.0003267828,0.00004517817,0.00006866646,0.0000775429,0.00007416038],"domain_scores_gemma":[0.9994398,0.00008280874,0.0001395801,0.00005803032,0.00005724081,0.0002224869],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8339249,0.02525121,0.009551071,0.003284491,0.003204309,0.0002566578,0.0004662128,0.0006424948,0.04278302,0.0002283156,0.002392844,0.07801444],"study_design_scores_gemma":[0.7585956,0.1981037,0.0334237,0.0001154659,0.002722443,0.0003715492,0.000107397,0.0006886908,0.002527782,0.0001334773,0.003170057,0.00004018831],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.991327,0.005570739,0.0003230774,0.0002610185,0.00006277874,0.001160136,0.0003464107,0.00004127014,0.0009075978],"genre_scores_gemma":[0.9917471,0.003354837,0.001344633,0.0006974435,0.0001375565,0.001327818,0.000683217,0.00001185096,0.000695496],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002513213,"threshold_uncertainty_score":0.01254499,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01355195460515869,"score_gpt":0.2571772653719167,"score_spread":0.243625310766758,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}